{"type":"trials","record":{"id":61,"source_id":"clinicaltrials-gov","external_id":"NCT07774000","title":"Efficacy of Topical Niacinamide Riboside on the Signs of Facial Skin Aging","brief_summary":"Niacinamide riboside (topical NR, also known as nicotinamide riboside) is an endogenous compound and a precursor (building block) to the essential cellular co-enzyme, nicotinamide adenine dinucleotide (NAD+). Research published by Maussudi et al. 2012 demonstrated that skin NAD+ levels were negatively correlated with age in both males and females, and aged skin was also correlated to an increase in DNA damage. Therefore, it is proposed that supporting skin NAD+ with precursors such as NR may be a strategy to combat DNA damage that leads to undesirable signs of skin aging, thus supporting skin cell resilience. The use of NR as a dietary supplement has produced effective, efficient, and reproducible increases in NAD+ in humans. However, the role of topically applied NR for skin aging requires further investigation. Though not measuring NAD+ directly, this study will explore if topically applied NR reduces the signs of skin aging that may result from cellular NAD+ deficiency. It is hypothesized that the addition of NR to a general skin care regimen will result in healthier, more youthful appearing skin over 12 weeks. The goal of this interventional clinical trial is to identify the most effective, tolerable, and efficient dose of NR for attenuating quantitative and qualitative indicators of facial skin aging in women ages 30-60. The three primary outcome measures are * Changes in skin biological age, * Quantitative reduction in fine lines and wrinkles near the eye, and * Changes in skin firmness and tightening. Secondary quantitative and qualitative outcomes include * Changes to pores, texture, redness, skin tone evenness, radiance, plumpness, and firmness on the global face. * Changes in skin moisture and skin barrier integrity, and * Participant perception of perceived efficacy, acceptability, and irritation. Skin imaging will also be employed in the study. Participants will be randomized into one of four test product groups: * Placebo * 2.5% NR, * 5% NR, or * 10% NR. The test product will be provided in a dry nanofiber sachet, and the percentage of NR is an estimate based on the final concentration of the applied material when mixed in serum. Following facial cleansing with the provided cleanser, study participants will prepare the test product (immediately before application) by dissolving a single sachet in the provided standardized gel serum. Following application, participants will apply the provided moisturizer and UV serum. Product application will occur twice daily for 84 days (12 weeks). In-clinic assessments will be performed at baseline and days 28, 56, and 84. Participants will also complete at home questionnaires on days 14 and 42. Adverse events and responses will be documented in participant diaries and immediately reported to the clinical research team.","overall_status":"Recruiting","phases":[],"study_type":"INTERVENTIONAL","sponsor":"ChromaDex, Inc.","enrollment":140,"countries":["South Africa"],"start_date":"2026-08-17","completion_date":"2027-03-31","last_update_date":"2026-08-21","source_url":"https://clinicaltrials.gov/study/NCT07774000","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-14T02:44:59.105435+00:00","last_seen_at":"2026-09-25T06:20:14.553+00:00","metadata":{"sex":"FEMALE","acronym":"NR-RADIANCE","age_range":"30 Years to 60 Years","comparator":"Placebo","organization":"ChromaDex, Inc.","interventions":["Topical niacinamide riboside","Placebo"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Change in skin's biological age — baseline and day 84","Quantitative change in fine lines and wrinkles — baseline and days 28, 56, and 84","Quantitative changes in skin firmness and tightness — baseline and days 56 and 84","Skin hydration — baseline and day 28","Moisture retention — baseline and day 28","Skin barrier integrity — baseline and day 28","Pores — baseline and days 28, 56, and 84","Texture/smoothness — baseline and days 28, 56, and 84","Skin tone evenness — baseline and days 28, 56, and 84","Skin plumpness — baseline and days 28, 56, and 84","Radiance — baseline and days 28, 56, and 84","Redness — baseline and days 28, 56, and 84","Firmness — baseline and days 28, 56, and 84","Participant Reported Outcome: Efficacy and acceptability of product — baseline and days 14, 28, 42, 56, and 84","Adverse Event Monitoring — Up to two weeks after study completion"],"design_description":"RANDOMIZED · PARALLEL · OTHER · QUADRUPLE","source_has_results":false},"controlled_terms":["Skin Aging on Face","Skin Care Dermocosmetics","Skin Care","Fine Lines and Wrinkles","Topical niacinamide riboside","Placebo"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":100,"publication_state":"published","match_explanation":"Title contains controlled term: skin aging.","quality_checked_at":"2026-09-25T06:20:17.523592+00:00","duplicate_cluster_key":"id:nct07774000","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2026-08-17 to 2027-03-31","comparator":"Placebo","confidence":"structured-source","population":"FEMALE · 30 Years to 60 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:14.555Z","intervention":["Topical niacinamide riboside","Placebo"],"participants":140,"study_design":"RANDOMIZED · PARALLEL · OTHER · QUADRUPLE","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Change in skin's biological age — baseline and day 84","Quantitative change in fine lines and wrinkles — baseline and days 28, 56, and 84","Quantitative changes in skin firmness and tightness — baseline and days 56 and 84","Skin hydration — baseline and day 28","Moisture retention — baseline and day 28","Skin barrier integrity — baseline and day 28","Pores — baseline and days 28, 56, and 84","Texture/smoothness — baseline and days 28, 56, and 84","Skin tone evenness — baseline and days 28, 56, and 84","Skin plumpness — baseline and days 28, 56, and 84","Radiance — baseline and days 28, 56, and 84","Redness — baseline and days 28, 56, and 84","Firmness — baseline and days 28, 56, and 84","Participant Reported Outcome: Efficacy and acceptability of product — baseline and days 14, 28, 42, 56, and 84","Adverse Event Monitoring — Up to two weeks after study completion"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"skin-aging","is_published":true,"match_reasons":["Title contains controlled term: skin aging.","Abstract contains controlled term: skin aging.","Source terminology contains: skin aging.","Title supplies longevity context: aging.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Skin ageing","slug":"skin-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/61","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}